Edition:
United States

Hisamitsu Pharmaceutical Co Inc (4530.T)

4530.T on Tokyo Stock Exchange

5,240JPY
9 Dec 2016
Change (% chg)

¥60 (+1.16%)
Prev Close
¥5,180
Open
¥5,140
Day's High
¥5,280
Day's Low
¥5,130
Volume
313,200
Avg. Vol
263,357
52-wk High
¥6,390
52-wk Low
¥4,455

4530.T

Chart for 4530.T

About

HISAMITSU PHARMACEUTICAL CO., INC. is a pharmaceutical company that operates in two business segments. The Medical and Related Product segment, along with its subsidiaries and associated companies, mainly manufactures and sells pharmaceuticals and related products in Japan, as well as the United States, Brazil, Vietnam, China... (more)

Overall

Beta: 0.71
Market Cap(Mil.): ¥498,664.09
Shares Outstanding(Mil.): 95.16
Dividend: 40.50
Yield (%): 1.54

Financials

  4530.T Industry Sector
P/E (TTM): 25.11 29.73 30.40
EPS (TTM): 208.68 -- --
ROI: 7.32 15.87 15.24
ROE: 7.85 16.99 16.58

BRIEF-Hisamitsu Pharmaceutical completes 2 mln shares' repurchase for 11.15 bln yen

* Says it completed repurchase of 2 million shares as scheduled on April 8, for 11.15 billion yen in total

Nov 21 2016

BRIEF-Hisamitsu Pharmaceutical repurchases 840,000 shares in October

* Says it repurchased 840,000 shares for 4,520,864,000 yen in total from Oct. 18 to Oct. 31

Nov 04 2016

BRIEF-Hisamitsu Pharmaceutical unit assigns rights for Brisdelle Capsules and Pexeva Tablets

* Says its U.S.-based unit, Noven Pharmaceuticals, Inc., has reached agreement to assign rights of approval for manufacture, commercialization and associated intellectual property for Brisdelle(Paroxetine) Capsules, 7.5 mg and Pexeva(Paroxetine Mesylate) Tablets to Sebela International Limited

Jul 26 2016

BRIEF-Hisamitsu Pharmaceutical sees sales down 4 pct to JPY 155 bln for FY 2017 - Nikkei

* Hisamitsu Pharmaceutical's operating profit apparently took a 13 pct hit for the march-May Quarter - Nikkei

Jun 27 2016

Earnings vs. Estimates